OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Kahl on the Rationale for Adding Bortezomib to BR Induction in MCL

May 19th 2025

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Dr Maroto-Martin on the Preliminary Efficacy of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 19th 2025

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

Dr Sobh on the Therapeutic Potential of Selectively Targeting NSD2 in Multiple Myeloma

May 19th 2025

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management

May 19th 2025

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

Dr Dreyling on Investigating ASCT Plus Ibrutinib and R-CHOP in Younger, Fit Patients With MCL

May 19th 2025

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer

May 19th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.

Dr Janjigian on Safety Considerations With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

May 19th 2025

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

Dr Winter on the Role of Treatment History in Richter Transformation

May 19th 2025

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

Dr Hunter on the Role of Momelotinib as First-Line Therapy in Myelofibrosis

May 19th 2025

Anthony M. Hunter, MD, discusses the role of momelotinib for the treatment of adult patients with myelofibrosis and moderate to severe anemia.

Dr Vlachou on the Rationale for Evaluating Perioperative Enfortumab Vedotin Plus Pembrolizumab in Upper Tract Urothelial CancerCancer

May 16th 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL

May 16th 2025

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Dr Ali on the Efficacy of CDK4/6 Inhibition in ER+, HER2+ Breast Cancer

May 16th 2025

Azka Ali, MD, discusses how data from the PATINA trial inform the role of CDK4/6 inhibition in ER-positive, HER2-positive breast cancer.

Dr Tarantino on the Potential Relevance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

May 16th 2025

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

Dr Maroto-Martin on the Development of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 16th 2025

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

May 16th 2025

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas

May 16th 2025

Erica Maria Pimenta, MD, discusses ongoing therapeutic and translational challenges in the treatment of soft tissue sarcomas.

Dr Bhat on Using BTK Degraders and Bispecific Antibodies to Address Challenges With R/R CLL Management

May 16th 2025

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Dr Yu on Factors Influencing PARP Inhibitor Selection in mCRPC

May 16th 2025

Evan Ya-Wen Yu, MD, discusses the PARP inhibitors that are available for the treatment of patients with mCRPC.

Dr Hall on Unmet Needs in Later-Line RCC

May 15th 2025

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

x